Allergy to sitagliptin or inactive ingredients Kidney disease or dialysis History of heart failure or pancreatitis Alcohol use, gallstones, high triglycerides Pregnancy or breastfeeding plans What drug interactions are there with Januvia
Oral GLP-1 drugs segment is expected to record the highest CAGR during the forecast period due to overcoming challenges of injections
Table of Contents Mold toxins are among the most under-recognized drivers of neuroinflammation and immune dysregulation in modern clinical practice
Upon binding, this receptor activation may trigger a series of intracellular events that potentially culminate in the release of stored growth hormone from somatotroph cells (GH-producing cells) in the anterior pituitary
Personalizing Your Semaglutide Plan with Genetic Insights Every person's metabolic response to semaglutide varies based on their genetic makeup
Type of Study: Retrospective observational cohort study Population: New users of GLP-1 RAs (semaglutide, tirzepatide, liraglutide) with overweight or obesity (BMI 27), regardless of type 2 diabetes status